Ruth H. Keogh, Sanja Stanojevic  Journal of Cystic Fibrosis 

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study  Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.
Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 
The prevalence of “risky behaviour” in adults with cystic fibrosis
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
Cystic fibrosis mortality trends in France
Zachary M. Sellers, Lori McGlocklin, Andrea Brasch 
Towards an individualized protocol for workload increments in cardiopulmonary exercise testing in children and adolescents with cystic fibrosis  H.J.
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,
Abaigeal D. Jackson, Christopher H. Goss  Journal of Cystic Fibrosis 
J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
Prospective randomized observer-blinded study comparing the analgesic efficacy of ultrasound-guided rectus sheath block and local anaesthetic infiltration.
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Nadav Traeger, Qiuhu Shi, Allen J. Dozor  Journal of Cystic Fibrosis 
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.
Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis  T.O. Hirche, H. Hirche, S. Jungblut,
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study  Matthew N. Hurley, Tricia M. McKeever,
Delayed publication of clinical trials in cystic fibrosis
The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited  Abaigeal D. Jackson, Leslie Daly,
Controlled clinical trials in cystic fibrosis — are we doing better?
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
The Journal of Cystic Fibrosis: Sunny perspectives
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis  Patrick John Lenehan, Craig M. Schramm, Melanie.
A.H. Gifford  Journal of Cystic Fibrosis 
Stroke and myocardial infarction following bronchial artery embolization in a cystic fibrosis patient  Matt Hoffman, Joseph P. Gerding, Jonathan B. Zuckerman 
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Physiologic endpoints for clinical studies for cystic fibrosis
Elisabeth P. Dellon, Elaine Chen, Jessica Goggin, Karen Homa, Bruce C
Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration  Drucy Borowitz, Daniel Gelfond, Karen.
Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor  Meredith C. Fidler, Jack Beusmans, Paul Panorchan,
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Chee Y. Ooi, Peter R. Durie  Journal of Cystic Fibrosis 
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands 
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic  Amanda L. Griffiths, Danielle F. Wurzel,
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Preemptive Bone Marrow Transplantation for FANCD1/BRCA2
American Journal of Kidney Diseases
Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale 
Higher risk of hospitalization among females with cystic fibrosis
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
Diabetes mellitus and survival in cystic fibrosis patients after lung transplantation  Markus Hofer, Christoph Schmid, Christian Benden, Rudolf Speich,
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Newsome S.J. , Daniel R.M. , Carr S.B. , Bilton D. , Keogh R.H.  
Do old pharmacokinetic parameter estimates predict new data?
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry  Sanja Stanojevic, Janet Stocks,
Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis  Ahmet Z. Uluer, David A. Waltz, Leslie.
Absence of a gender gap in survival
Presentation transcript:

A guide to interpreting estimated median age of survival in cystic fibrosis patient registry reports  Ruth H. Keogh, Sanja Stanojevic  Journal of Cystic Fibrosis  Volume 17, Issue 2, Pages 213-217 (March 2018) DOI: 10.1016/j.jcf.2017.11.014 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Illustrations contrasting the period approach and the birth cohort approach. Lines represent 12 individuals followed-up during 1st January 1985–31st December 2015. Individuals 1 and 2 were born prior to 1985 and individuals 1, 4, 8 and 11 were known to be alive at the end of follow-up. Individual 7 was lost-to-follow-up. Individuals 2 and 10 do not contribute to either analysis. Journal of Cystic Fibrosis 2018 17, 213-217DOI: (10.1016/j.jcf.2017.11.014) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Estimated survivor curves using data from the UK Cystic Fibrosis Registry. The shaded area shows the 95% confidence intervals and the down-arrow indicates the estimated median survival age. Estimates are based on the period approach using data on 10,946 individuals and 654 deaths observed in the 5-year period 1st January 2011–31st December 2015. Journal of Cystic Fibrosis 2018 17, 213-217DOI: (10.1016/j.jcf.2017.11.014) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 The upper plot shows estimates of median age of survival, conditional on survival to a given age. The dots show the estimated conditional median age of survival from each age and the bars show the 95% CIs. Estimates are based on the period approach using data on individuals observed in the 5-year period 1st January 2011–31st December 2015. The lower plots show the estimated conditional survival curves from ages 30 and 40 indicating the conditional median age of survival. Supplementary Fig. 1 shows estimates for males and females separately. Journal of Cystic Fibrosis 2018 17, 213-217DOI: (10.1016/j.jcf.2017.11.014) Copyright © 2017 The Authors Terms and Conditions